Partner Investment Management L.P. decreased its position in Edwards Lifesciences Corp (NYSE:EW) by 12.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 10,184 shares of the medical research company’s stock after selling 1,506 shares during the quarter. Edwards Lifesciences comprises approximately 1.2% of Partner Investment Management L.P.’s portfolio, making the stock its 25th largest holding. Partner Investment Management L.P.’s holdings in Edwards Lifesciences were worth $1,482,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Worldquant Millennium Quantitative Strategies LLC bought a new position in Edwards Lifesciences during the second quarter valued at about $2,480,000. Centaurus Financial Inc. bought a new position in Edwards Lifesciences during the second quarter valued at about $114,000. Metropolitan Life Insurance Co. NY grew its position in Edwards Lifesciences by 1.2% during the second quarter. Metropolitan Life Insurance Co. NY now owns 42,171 shares of the medical research company’s stock valued at $6,139,000 after buying an additional 484 shares during the period. grace capital bought a new position in Edwards Lifesciences during the second quarter valued at about $2,483,000. Finally, Colony Group LLC grew its position in Edwards Lifesciences by 43.4% during the second quarter. Colony Group LLC now owns 50,820 shares of the medical research company’s stock valued at $7,398,000 after buying an additional 15,377 shares during the period. Hedge funds and other institutional investors own 82.11% of the company’s stock.

In other news, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $145.57, for a total value of $800,635.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 25,000 shares of the stock in a transaction dated Tuesday, July 3rd. The stock was sold at an average price of $145.67, for a total transaction of $3,641,750.00. Following the completion of the sale, the chief financial officer now directly owns 41,265 shares in the company, valued at $6,011,072.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 145,411 shares of company stock worth $20,846,271. Insiders own 1.84% of the company’s stock.

EW has been the subject of several research reports. BMO Capital Markets increased their price target on shares of Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research report on Tuesday, July 10th. ValuEngine upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th. Royal Bank of Canada increased their price target on shares of Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research report on Wednesday, May 23rd. Northland Securities reiterated a “hold” rating and set a $120.00 target price on shares of Edwards Lifesciences in a research report on Friday, July 27th. Finally, JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and an average price target of $152.45.

Shares of NYSE:EW opened at $144.92 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. The stock has a market cap of $30.13 billion, a price-to-earnings ratio of 38.14, a price-to-earnings-growth ratio of 1.99 and a beta of 0.57. Edwards Lifesciences Corp has a twelve month low of $100.20 and a twelve month high of $156.87.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The firm had revenue of $972.00 million during the quarter, compared to analyst estimates of $968.32 million. During the same quarter last year, the business earned $1.08 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. analysts predict that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.